CART-19 Cells for R/R B-cell Lymphoma

CART-19 Cells For Patients With Relapsed or Refractory B-cell Lymphoma

Relapsed/Refractory B Cell Lymphoma is a challenge to be treated, however,CART-19 cells could be very promosing. This study aims to assess the safety and toxicity of CART-19 cells for patients with relapse or refractory B cell lymphoma.

Inclusion Criteria:

• Signed written informed consent
• Aged between 1-65 years
• Patients with relapse/refractory B-cell lymphoma
• Cardiac: Left ventricular ejection fraction ≥ 50%
• Adequate renal and hepatic function
• Performance status: Karnofsky ≥ 70%

Exclusion Criteria:

• Pregnant or lactating females.
• Any co-morbidity precluding the administration of CART-19 cells.